Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis.
Clinical Decision-Making
Coronary Artery Disease
/ diagnosis
Drug Administration Schedule
Dual Anti-Platelet Therapy
Hemorrhage
/ chemically induced
Humans
Ischemia
/ diagnosis
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ administration & dosage
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Aspirin
Clopidogrel
Dual antiplatelet therapy
P2Y(12) inhibitor
Prasugrel
Ticagrelor
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
25
11
2020
revised:
22
12
2020
accepted:
17
03
2021
pubmed:
24
3
2021
medline:
27
11
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
The ideal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still unknown. In this meta-analysis, we aimed to compare very short-term (1-3 months), short-term (6 months), standard-term (12 months) and long-term (>12 months) DAPT durations for efficacy and safety. Overall DAPT comparisons were classified as "any shorter-term"/"any longer-term" DAPT. The primary outcome was a composite of major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke and cardiovascular death). The primary safety outcome was major bleeding. Twenty-six studies comprising 103.394 patients were included. Compared with standard-term DAPT duration, very short-term DAPT duration with subsequent drop of aspirin (RR 1.06, 95% CI, 0.95-1.18, p = 0.26) or drop of the P2Y DAPT may be shortened to 1-3 months in patients with low ischemic but high bleeding risk followed by aspirin or P2Y CRD42020163719.
Identifiants
pubmed: 33753284
pii: S1537-1891(21)00030-6
doi: 10.1016/j.vph.2021.106858
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106858Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.